We investigated nasopharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus among infants and young children with acute otitis media in a country where use of 7-valent pneumococcal conjugate vaccine (PCV7) has been progressively implemented. Among 1783 children enrolled, 60.8% carried S. pneumoniae, and 9% carried S. aureus. Among S. pneumoniae carriers, the rate of S. aureus carriage was 8.4%, compared with 9.9% among S. pneumoniae noncarriers. The rate of S. pneumoniae carriage in the PCV7-vaccinated population was lower (59.8%) than that observed in the nonvaccinated population (66.2%;
species by another [2] . One study reported an increased rate of Staphylococcus aureus culture-positive otorrhea in otitisprone children aged 1-5 years who had received both 7-valent pneumococcal conjugate vaccine (PCV7) and a booster dose of pneumococcal polysaccharide vaccine [3] . Three subsequent studies suggested that, among patients who had not received PCV7, S. pneumoniae carriage (specifically for vaccine-type strains) is negatively associated with S. aureus carriage in children [4] [5] [6] . Moreover, the increasing prevalence of communityacquired methicillin-resistant S. aureus (MRSA) infection in some regions of the world is of concern [7] . In September 2001, when PCV7 was introduced in France, a national surveillance network of nasopharyngeal carriage of S. pneumoniae in children aged 6-24 months who had acute otitis media (AOM) was created to observe trends in S. pneumoniae serotypes and antibiotic resistance. The initial 3-year results of this surveillance were recently published elsewhere [8] . Since 2003, when the negative interaction between S. pneumoniae and S. aureus was suggested [3] , surveillance was extended to S. aureus carriage, to investigate the possible association between both pathogens by studying their prevalence and risk factors for carriage in young children in an area where PCV7 immunization was progressively implemented [8] .
Patients and methods. The study was approved by the Saint Germain en Laye Ethics Committee (France). Informed consent was obtained from all parents.
Since September 2001, a total of 103 pediatricians distributed throughout France have taken part in this prospective study. Subsequently, from September through June of each year, children (age, 6-24 months) of either sex who had AOM were enrolled. Children were excluded from the study for the following reasons: receipt of antibiotic treatment within 7 days before enrollment, presence of a severe underlying disease, or previous inclusion in the study during the prior 12 months. We queried the parents or guardians regarding each subject's demographic information, known risk factors for carriage of drug-resistant bacteria (including the use of antibiotics during the previous 3 months), and the history of PCV7 immunization.
Nasopharyngeal specimens were obtained with cottontipped wire swabs. The swabs were inserted into the anterior nares, gently rubbed on the nasopharyngeal wall, removed, and immediately placed in transport medium (culture swab transport system; Copan Venturi Transystem). The samples obtained were transferred in р48 h to the French National Reference Centre for Pneumococci (Paris). S. pneumoniae culture, identification, serotyping, and antibiotic susceptibility testing were performed as described elsewhere [8] . Since December 2003, nasopharyngeal samples have also been screened for the presence of S. aureus using selective agar plates (SAID; bioMérieux). S. aureus was identified on the basis of colony morphology and catalase and coagulase production; antimicrobial susceptibility was determined using the agar diffusion method, with the following disks: oxacillin, erythromycin, clindamycin, tetracycline, trimethoprim-sulfamethoxazole, rifampin, and ofloxacin. In addition, identification of S. aureus together with the presence of both mecA and the PantonValentine leukocidin gene pvl were assessed by PCR and reverse-hybridization using GenoType MRSA DNA strips (Biocentric), in accordance with the manufacturer recommendations. Data were double entered into 4D software, version 6.4 (4D), and statistical analysis was performed using SAS software, version 8.02 (SAS Institute). ORs and P values (by x 2 test) were calculated to assess risk factors for carriage of each pathogen, which included age, sex, presence of siblings aged !6 years, day care attendance, pneumococcal immunization status, and receipt of antibiotic treatment in the previous 3 months. Variables identified in the univariate analysis were introduced into multivariate logistic regression models to evaluate their independent contributions (expressed as ORs with 95% CIs).
Results. A total of 1783 children (age, 6-24 months) were enrolled during the period from December 2003 through June 2006. Nasopharyngeal swab specimens were cultured for both S. pneumoniae and S. aureus. Fifty-five percent of the children were male, and the mean age (‫ע‬SD) was months. 13.9 ‫ע‬ 5.3 Seventeen percent of the children had been immunized, and the majority of vaccinated patients were correctly vaccinated for their age: among 647 children aged !1 year, 7.1% had received 1 dose of vaccine, 16.1% had received 2 doses, and 76.8% had received 3 doses; for the 824 children aged у1 year, 4.2% had received 1 dose of vaccine, 18.5% had received 2 doses, and 77.3% had received у3 doses.
Vaccinated children (who received у1 dose) were younger (mean , months) than nonvaccinated chilage ‫ע‬ SD 13.7 ‫ע‬ 5.0 dren (mean , months; ). S. pneuage ‫ע‬ SD 14.8 ‫ע‬ 6.2 P p .01 moniae and S. aureus were isolated from 1085 children (60.8%) and 160 children (9%), respectively. The proportions of children who carried S. aureus alone or both S. aureus and S. pneumoniae were similar among vaccinated children (3.9% and 5.1%, respectively) and nonvaccinated children (3.5% and 5.1%, respectively). In the univariate analysis (table 1), the rate of carriage of S. aureus was lower among children in day care centers (6.6% vs. 10.2%;
) and among children with P p .01 young siblings (7.4% vs. 11.2%;
), but the difference in P p .01 S. aureus carriage rates between children aged у1 year and those who were younger did not reach statistical significance (7.9% vs. 10.5%;
). In the multivariate analysis, the risk P p .06 factors of day care center attendance (OR, 0.60; 95% CI, 041-0.88:
) and sibling aged !6 years in day care or at P p .009 school (OR, 0.57; 95% CI, 0.41-0.79; ) were inversely P ! .001 related to S. aureus carriage. Table 2 shows the effect of PCV7 immunization on pneumococcal and staphylococcal carriage in children aged 13-24 months. Diminution of pneumococcal carriage in vaccinated children decreased dramatically only after the booster dose. Before the booster dose, the decrease involved only vaccine types. In contrast to the dramatic effect on pneumococcal carriage, vaccination was not found to alter staphylococcal carriage rates. The rate of drug-resistant S. aureus isolates was 13% for methicillin, 34% for erythromycin, 16% for clindamycin, 2% for rifampin, 8% for tetracycline, 1% for trimethoprim-sulfamethoxazole, and 22% for ofloxacin. All MRSA isolates were found to harbor the mecA gene, but none harbored the pvl gene. Among the S. aureus carriers, the rate of MRSA carriage did not appear to be influenced by antibiotic treatment during the past 3 months (10.6% for the children who had received antibiotics, compared with 14.9% for children who had not; OR, 0.68; 95% CI, 0.26-1.78;
). P p .43 Discussion. Nasopharyngeal carriage of S. aureus and S. pneumoniae can lead to spread of the organisms and to disease-to local diseases (e.g., otitis media, sinusitis, and nonbacteremic pneumonia) and to invasive diseases (e.g., sepsis and meningitis). S. pneumoniae is carried in the nasopharynx by most children during early childhood but infrequently by adults [1, 5] . Conversely, S. aureus is carried by ∼10% of young children aged !2 years and by ∼35% of the general adult population [3, 5, 9] . S. aureus is carried most consistently in the nares, whereas S. pneumoniae is more frequently isolated from the nasopharynx. Recently, a study suggested an added value of throat sample for adults [1, 5, 6, 9, 10] . Three studies have suggested that, in patients who have not been vaccinated with PCV7, S. pneumoniae carriage (specifically for vaccine-type strains) is negatively associated with S. aureus carriage in children [4] [5] [6] . Recently, McNally et al. [11] studied South African children with severe pneumonia and confirmed the inverse relationship between nasopharyngeal carriage of S. pneumoniae and S. aureus in HIV-negative patients; on the other hand, they also found a lack of association between nasopharyngeal carriage of the 2 bacterial species in HIV-infected children.
In this study's population of young children with AOM, we did not observe an effect of PCV7 immunization status on nasopharyngeal carriage of S. aureus. To our knowledge, this study is the first to compare the S. aureus nasopharyngeal carriage in PCV7-vaccinated children with that in children who have not received PCV7.
The rate of S. pneumoniae carriage (60.8%) reported here is much higher than the rates reported in the 4 studies that suggested interference between S. pneumoniae and S. aureus carriage: 47% in the study by McNally et al. [11] , 43% in the first study by Regev-Yochay et al. [5] , 19% in the study by Bogaert et al. [4] , and 35% in the second study by Regev-Yochay et al. [6] . The younger age of the children enrolled in our study, as well as the clinical features with which they presented (likely related to pneumococcal AOM), may explain these discrepancies [12] .
It is worthwhile to note that the factors known to increase carriage of S. pneumoniae (i.e., day care center attendance, presence of siblings, and age) in many studies were associated with a decrease in the rate of carriage of S. aureus. On the other hand, the same factors may increase the carriage rate for other pathogens, such as Haemophilus influenzae or Moraxella catarrhalis [12] . It is important to note that these findings were observed in a population of young children (age, !2 years) who presented with clinical signs and symptoms of AOM and, thus, may not be widely applicable to other populations. There are several limitations to the present study. First, the other bacterial species potentially involved in bacterial interference were not studied. Second, the present study was cross-sectional; a longitudinal study would be required to determine a causal relationship between carriage of the 2 bacterial species. Third, unlike the studies by Regev-Yochay et al. [5, 6] , in which 1 nasal sample and 1 nasopharyngeal sample were obtained from each patient, we collected only 1 nasopharyngeal sample from each patient. The study would have been more conclusive if nasal and nasopharyngeal samples had been obtained. However, the same procedure was used for vaccinated and unvaccinated children, and the rate of S. aureus carriage in our study is closely comparable with the rate reported for young children by RegevYochay et al. [5, 6] and Bogaert et al. [4] .
In conclusion, this study does not support an association between nasopharyngeal carriage of S. pneumoniae and S. aureus in children aged !2 years who have AOM. However, without prospective interventional studies that include healthy children and additional pathogens, it will be difficult to confirm or exclude the effect of PCV7 on S. aureus carriage.
